Epilepsy; Seizure Clinical Trial
Official title:
Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy
This project studies how 2-deoxy-glucose (2DG) pills are absorbed and distributed in people with epilepsy. 2DG is similar to glucose, the main energy source for the brain, but it cannot be used as energy. During seizures, neurons are at a very high metabolic state with huge glucose metabolism as glycolysis is accelerated to supply the high metabolic needs of a seizure. 2DG is taken up by cells but cannot be metabolized by the first enzyme in the glycolytic pathway, thus is stops, or "clogs up", glycolysis. Since brain metabolism is almost entirely dependent on glucose as an energy source, glycolysis is arrested and may stop seizures. It is hoped that 2DG will stop seizures by interfering with the brain's energy use. This is an open-label phase 2 study of the pharmacokinetics (PK), safety, and tolerability of 2DG administered orally to adult epilepsy patients. A 3-level 2DG dose escalation is planned in sequential cohorts of 3 subjects in each cohort with review of each cohort before proceeding to the next cohort. On the day of oral 2DG exposure, subjects will receive a single dose of 40 mg in the first cohort, a single dose of 60 mg in the second cohort, and two 60 mg doses (60 mg bid) in the third cohort. After 3 subjects have completed dosing at Dose Level 1 (40 mg/day), the safety and PK results will be reviewed. The Study Committee will determine if the next cohort should be enrolled at Dose Level 2 (60 mg/day). The same procedure will be repeated to determine if the next cohort should be enrolled at Dose Level 3 (60 mg bid = 120 mg/day). If the Study Committee determines that the most recent dose is not tolerated or that there are significant adverse events, the subsequent Dose Level will not be enrolled. A standard time-concentration curve will be constructed from the 2DG levels obtained from the PK blood draws. Parameters will be calculated for: time to maximum concentration (tmax), maximum concentration (Cmax), elimination rate, half-life (t1/2), AUC, and derived parameters. Statistical analysis will not be performed because of the small n, but this will nevertheless establish the PK profile of 2DG in people with epilepsy. The most important parameter will be the AUC which determines drug exposure.
The study will be conducted as a 1-day Monitored Dosing and Pharmacokinetics Period in an inpatient setting. Subjects will report to the hospital in a fasted state (since midnight) on the morning of the pharmacokinetics study. Subjects will continue to fast until one hour after the 2DG dose has been given. 2DG will be given as either a single oral dose (40 mg for Dose Level 1; 60 mg for dose level 2) or 60 mg bid (Dose Level 3). Blood for pharmacokinetic analysis will be drawn at time 0 (prior to drug administration), and then at 15, 30, 45, and 60 minutes and at 2, 4, 6, 12, and 24 hours after single dose 2DG administration. Blood for pharmacokinetic analysis will be drawn at time 0 (prior to drug administration) and then at 15, 30, 45, and 60 minutes and at 2, 4, 6, 12, and 24 hours after the last dose for Dose Level 3. Patients will be closely monitored for safety during and following dosing with 2DG. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03548779 -
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
|
N/A | |
Completed |
NCT05257811 -
Earbud EEG Feasibility Study
|
||
Completed |
NCT05066880 -
Yoga and Aerobic Exercise in Epilepsy
|
N/A | |
Recruiting |
NCT06278428 -
Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age
|
||
Terminated |
NCT04639310 -
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
|
Phase 3 | |
Withdrawn |
NCT04737174 -
ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors
|
Phase 2 | |
Not yet recruiting |
NCT06275685 -
Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking
|
N/A | |
Completed |
NCT04822662 -
The Individual and Family Self Management Theory Based Epilepsy Education Program's Effectiveness
|
N/A | |
Recruiting |
NCT04759196 -
Generating Evidence on NonEpileptic, Stereotypical and Intermittent Symptoms (NESIS) in Chronic Subdural Hematomas
|
Phase 4 | |
Completed |
NCT04171934 -
Clinical Validation of a Video-based Epilepsy Examination Service
|
||
Recruiting |
NCT04569708 -
Sleep Spindles and Memory in Rolandic Epilepsy
|
N/A | |
Completed |
NCT04311151 -
Impact of Self-visualization of Epileptic Seizures on Patients' Perception of the Disease and Risk Behavior
|
N/A | |
Not yet recruiting |
NCT05635396 -
Seizures Detection in Real Life Setting
|
N/A | |
Completed |
NCT05675254 -
The Prevalence and Risk Factors of Coagulopathy in Pediatric Epilepsy Surgery Patients
|
||
Terminated |
NCT04912856 -
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
|
Phase 3 | |
Recruiting |
NCT04221282 -
ZEBinix® Retention Rate in Epilepsy in Elderly Patients
|